Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…
Read News Item
Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…
Read News Item
The Center for Alternatives to Animal Testing and the Animal-Free Safety Assessment recently held their annual meeting on advancing toxicity testing in the 21st century…
Read News Item
Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…
Read News Item